No Cover Image

Journal article 102 views 12 downloads

The Inflammatory Response to Ventricular Assist Devices / Gemma Radley; Ina Laura Pieper; Sabrina Ali; Farah Bhatti; Catherine A. Thornton

Frontiers in Immunology, Volume: 9

Swansea University Author: Thornton, Catherine

  • 45954.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution License (CC-BY).

    Download (744.45KB)

Abstract

The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complication...

Full description

Published in: Frontiers in Immunology
ISSN: 1664-3224
Published: 2018
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa45954
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2018-11-16T20:18:30Z
last_indexed 2019-01-14T14:00:20Z
id cronfa45954
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-01-14T12:34:34Z</datestamp><bib-version>v2</bib-version><id>45954</id><entry>2018-11-16</entry><title>The Inflammatory Response to Ventricular Assist Devices</title><alternativeTitle></alternativeTitle><author>Catherine Thornton</author><firstname>Catherine</firstname><surname>Thornton</surname><active>true</active><ORCID>0000-0002-5153-573X</ORCID><ethesisStudent>false</ethesisStudent><sid>c71a7a4be7361094d046d312202bce0c</sid><email>0789291f2bbb8aeb948db2352e425e6a</email><emailaddr>70js5AkMS5jPo3arCUY9c32HZhUyFASdV1DFdgIIhKs=</emailaddr><date>2018-11-16</date><deptcode>PMSC</deptcode><abstract>The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient&#x2019;s inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.</abstract><type>Journal article</type><journal>Frontiers in Immunology</journal><volume>9</volume><journalNumber/><paginationStart/><paginationEnd/><publisher></publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint/><issnElectronic>1664-3224</issnElectronic><keywords>Heart failure; Ventricular Assist Devices; Inflammation; Cytokines; Leukocytes</keywords><publishedDay>15</publishedDay><publishedMonth>11</publishedMonth><publishedYear>2018</publishedYear><publishedDate>2018-11-15</publishedDate><doi>10.3389/fimmu.2018.02651</doi><url></url><notes></notes><college>Swansea University Medical School</college><department>Medicine</department><CollegeCode>CMED</CollegeCode><DepartmentCode>PMSC</DepartmentCode><institution/><researchGroup>Microbes and immunity</researchGroup><supervisor/><sponsorsfunders/><grantnumber/><degreelevel/><degreename>None</degreename><lastEdited>2019-01-14T12:34:34Z</lastEdited><Created>2018-11-16T13:37:20Z</Created><path><level id="1">Swansea University Medical School</level><level id="2">Medicine</level></path><authors><author><firstname>Gemma</firstname><surname>Radley</surname><orcid/><order>1</order></author><author><firstname>Ina Laura</firstname><surname>Pieper</surname><orcid/><order>2</order></author><author><firstname>Sabrina</firstname><surname>Ali</surname><orcid/><order>3</order></author><author><firstname>Farah</firstname><surname>Bhatti</surname><orcid/><order>4</order></author><author><firstname>Catherine A.</firstname><surname>Thornton</surname><orcid/><order>5</order></author></authors><documents><document><filename>0045954-06122018160258.pdf</filename><originalFilename>45954.pdf</originalFilename><uploaded>2018-12-06T16:02:58Z</uploaded><type>Output</type><contentLength>962756</contentLength><contentType>application/pdf</contentType><version>VoR</version><cronfaStatus>true</cronfaStatus><action>Published to Cronfa</action><actionDate>06/12/2018</actionDate><embargoDate>2018-12-05T00:00:00</embargoDate><documentNotes>Released under the terms of a Creative Commons Attribution License (CC-BY).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents></rfc1807>
spelling 2019-01-14T12:34:34Z v2 45954 2018-11-16 The Inflammatory Response to Ventricular Assist Devices Catherine Thornton Catherine Thornton true 0000-0002-5153-573X false c71a7a4be7361094d046d312202bce0c 0789291f2bbb8aeb948db2352e425e6a 70js5AkMS5jPo3arCUY9c32HZhUyFASdV1DFdgIIhKs= 2018-11-16 PMSC The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient’s inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy. Journal article Frontiers in Immunology 9 1664-3224 Heart failure; Ventricular Assist Devices; Inflammation; Cytokines; Leukocytes 15 11 2018 2018-11-15 10.3389/fimmu.2018.02651 Swansea University Medical School Medicine CMED PMSC Microbes and immunity None 2019-01-14T12:34:34Z 2018-11-16T13:37:20Z Swansea University Medical School Medicine Gemma Radley 1 Ina Laura Pieper 2 Sabrina Ali 3 Farah Bhatti 4 Catherine A. Thornton 5 0045954-06122018160258.pdf 45954.pdf 2018-12-06T16:02:58Z Output 962756 application/pdf VoR true Published to Cronfa 06/12/2018 2018-12-05T00:00:00 Released under the terms of a Creative Commons Attribution License (CC-BY). true eng
title The Inflammatory Response to Ventricular Assist Devices
spellingShingle The Inflammatory Response to Ventricular Assist Devices
Thornton, Catherine
title_short The Inflammatory Response to Ventricular Assist Devices
title_full The Inflammatory Response to Ventricular Assist Devices
title_fullStr The Inflammatory Response to Ventricular Assist Devices
title_full_unstemmed The Inflammatory Response to Ventricular Assist Devices
title_sort The Inflammatory Response to Ventricular Assist Devices
author_id_str_mv c71a7a4be7361094d046d312202bce0c
author_id_fullname_str_mv c71a7a4be7361094d046d312202bce0c_***_Thornton, Catherine
author Thornton, Catherine
author2 Gemma Radley
Ina Laura Pieper
Sabrina Ali
Farah Bhatti
Catherine A. Thornton
format Journal article
container_title Frontiers in Immunology
container_volume 9
publishDate 2018
institution Swansea University
issn 1664-3224
doi_str_mv 10.3389/fimmu.2018.02651
college_str Swansea University Medical School
hierarchytype
hierarchy_top_id swanseauniversitymedicalschool
hierarchy_top_title Swansea University Medical School
hierarchy_parent_id swanseauniversitymedicalschool
hierarchy_parent_title Swansea University Medical School
department_str Medicine{{{_:::_}}}Swansea University Medical School{{{_:::_}}}Medicine
document_store_str 1
active_str 1
researchgroup_str Microbes and immunity
description The therapeutic use of ventricular assist devices (VADs) for end-stage heart failure (HF) patients who are ineligible for transplant has increased steadily in the last decade. In parallel, improvements in VAD design have reduced device size, cost, and device-related complications. These complications include infection and thrombosis which share underpinning contribution from the inflammatory response and remain common risks from VAD implantation. An added and underappreciated difficulty in designing a VAD that supports heart function and aids the repair of damaged myocardium is that different types of HF are accompanied by different inflammatory profiles that can affect the response to the implanted device. Circulating inflammatory markers and changes in leukocyte phenotypes receive much attention as biomarkers for mortality and disease progression. However, they are seldom used to monitor progress during and outcomes from VAD therapy or during the design phase for new devices. Even the partial reversal of heart damage associated with heart failure is a desirable outcome from VAD use. Therefore, improved understanding of the interplay between VADs and the recipient’s inflammatory response would potentially increase their uptake, improve patient lives, and fuel research related to other blood-contacting medical devices. Here we provide a review of what is currently known about inflammation in heart failure and how this inflammatory profile is altered in heart failure patients receiving VAD therapy.
published_date 2018-11-15T16:24:57Z
_version_ 1639591494314622976
score 10.827766